Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marcio Silva De'Souza
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 168
- Beta
- 2.78
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 99.25
Financials
Revenue
$0.00-100.0%Net Income
$-83.72MEBITDA
$-83.69MFree Cash Flow
$-77.89MEPS (diluted)
$-2.87Shares Outstanding (diluted)
29.13M+29575.6%Operating Expenses
$96.90MCash & Debt
$758.55MReturn of Capital
$0.00Revenue by Segment (annual)
$11.20MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-303.27M | $-13.48 |
| 2024 | $8.55M | $-182.82M | $-10.21 |
| 2023 | $2.45M | $-123.28M | $-18.69 |
| 2022 | $0.00 | $-214.03M | $-69.33 |
| 2021 | $0.00 | $-167.06M | $-58.96 |
| 2020 | $0.00 | $-61.82M | $-103.61 |
| 2019 | $0.00 | $-35.51M | $-348.24 |
| 2018 | $0.00 | $-26.54M | $-306.73 |
Valuation
PRAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
172+243.33%Social Signal Score
Mentions (4)
- News (RSS)seekingalpha·23d ago·Positive
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
View source ↗ - Newsseekingalpha.com·23d ago·Positive
…ine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers.
View source ↗ - News (Marketaux)gurufocus.com·35d ago·Positive
Velan Capital Investment Management LP Expands Edesa Biotech Inc (EDSA) Stake The firm's top holdings include Sutro Bi[+183 characters]
View source ↗ - News (RSS)investing·49d ago·Neutral
Praxis Precision Medicines stock hits 52-week high at 388.27 USD
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-3.66 per share
Typical surprise +2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-2.87 vs $-3.67beat
- Thu, May 7$-3.20 vs $-3.58beat
- Thu, Feb 19$-3.50 vs $-3.13miss
- Wed, Nov 5$-3.36 vs $-3.45beat
- Mon, Aug 4$-3.31 vs $-3.40beat
- Fri, May 2$-3.29 vs $-3.20miss
Estimates and results for PRAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRAX officers and directors.
- Bought
- —
- Sold
- $10.7m
0 trades
17 trades
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
- Desimone Jillsold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 7, 2026 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.